BHV-5000

DB17817ExperimentalSmall molecule

BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is lanicemine.

Also known as: (S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate
Code names: BHV-5000

What you can answer from here — as of March 06, 2025

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of BHV-5000, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account